13 hrs ago | finance.yahoo.com
By Grant Zeng, CFA NWBO Reports First Quarter of 2013 Financials On May 16, Northwest Biotherapeutics (Nasdaq-small:NWBO) filed its 10-Q for the first quarter of 2013. There was no revenue for the first ...
Read more...
DCVax-Direct NWBO tumor DCVax-L cancer trial Phase DCVax®-Direct
16 hrs ago | checkorphan.org
Cellular Biomedicine Group announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell...
Read more...
TC-DC cell enrollment therapy Biomedicine cellular trial clinical HCC liver tumor patient CBMG phase immune recurrence
14 hrs ago | firmenpresse.de
SAN FRANCISCO, CA -- (Marketwired) -- 05/23/13 -- Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic...
Read more...
Pexa-Vec Jennerex tumor $21.6 cancer oncolytic Phase TRAVERSE
14 hrs ago | finanznachrichten.de
BUSAN, South Korea, May 23, 2013 /PRNewswire/ -- Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of...
Read more...
SillaJen Pusan JX-594 Translational Yangsan Jennerex oncolytic clinical research PNUYH
14 hrs ago | newsblaze.com
Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that it has...
Read more...
Jennerex $21.6 placement tumor Pexa-Vec private oncolytic complete immunotherapy
12 hrs ago | retractionwatch.wordpress.com
The editor of Clinical Medicine Insights: Oncology has issued an Expression of Concern over a 2008 paper by a group of authors in China after identifying “flaws” in one of the figures. The article, “Exvivo experiments of human...
Read more...
journal cord Expression Concern oncology Exvivo exosomes ascites-derived blood dendritic paper immunotherapy umbilical ovarian COPE figure 10.4137 CMO.S776 Yue-Cheng 2008;2;461 Qi-Ling
11 hrs ago | bio-medicine.org
BETHESDA, Md. , May 23, 2013 /- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW Bio), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, announced today that it will use its exhibit...
Read more...
ASCO Bio NW Exhibit DCVax immune therapy oncologist tumor cancer
14 hrs ago | finanznachrichten.de
NEW BRUNSWICK, N.J., May 23, 2013 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they anticipate submitting more than...
Read more...
Johnson&Johnson Janssen Pharmaceuticals product NMEs www.investor.jnj.com 2017 pharmaceutical pipeline innovation treatment
4 hrs ago | bullfax.com
By Chris Lacoursiere : The annual conference of The American Society of Clinical Oncology (ASCO) is currently less than a few days away, and what is the buzz for this year's conference? Immunotherapy is the buzz word for this...
Read more...
Peregrine immunotherapy pharmaceutical Golden PD-L1 off-switch Bavituximab PD-1 PS phosphatidylserine immune MAB
2 hrs ago | bbc.co.uk
They were thought to clear a path for cancer cells, but now MMP enzymes have been shown to help the immune system attack the tumour Enzymes released by cancerous cells have a protective function and are not one of the "bad...
Read more...
MMP-8 enzyme cancer cell tumor breast immune cop MMPs IL-8
14 hrs ago | skynews.com.au
Targeting specific cells in the body can reverse the effects of cancer on the immune system, West Australian researchers say. The study focussed on the immune system's ability in older people to deal with cancers. It tracked...
Read more...
All similar articles: 54 »
cancer immune WA Jackaman cell macrophages research Curtin elderly tumour-induced CHIRI system mimicked activate Dr
14 hrs ago | sectorpublishingintelligence.co.uk
World News: 12:30 GMT Thursday 23rd May 2013. [Advaxis, Inc. via Businesswire] Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it...
Read more...
Advaxis proxy Trials.gov supplement Identifier cancer filing immunotherapy Clinical stock post-reverse statement proposal
6 hrs ago | physorg.com
—New tension gauge tether (TGT) laboratory method developed at the University of Illinois at Urbana-Champaign has broad applications for research into stem cells, cancer, infectious disease, and immunology.
Read more...
cell pN adhesion integrin biophysicist tether University of Illinois molecular activate tension ligand TGT pico-Newtons strand integrin-ligand molecule cellular Wang tolerance
11 hrs ago | firmenpresse.de
College of Pharmacy Partners With TNI BioTech to Develop New Drugs for Africa (firmenpresse) - WASHINGTON, DC -- (Marketwired) -- 05/23/13 -- Howard University College of Pharmacy has signed a multi-year agreement with TNI...
Read more...
BioTech TNI Pharmacy Howard Africa drug College pharmaceutical
May 22, 2013 | medicalnewstoday.com
Using bacteria to ferry radioisotopes commonly used in cancer therapy directly into pancreatic cancer cells in mice, researchers in the US were able dramatically to reduce the number of secondary tum...
Read more...
All similar articles: 67 »
pancreatic cancer Gravekamp bacterium radioactive Listeria Dadachova tumor mouse cell spread rhenium
May 22, 2013 | prostate.net
Sipuleucel-T vs Radium-223 for Prostate Cancer Sipuleucel-T vs radium-223 compares two medications for late-stage castration-resistant prostate cancer. Sipuleucel-T has been available since April 2010, but now with the FDA...
Read more...
Sipuleucel-T Radium-223 vs Prostate cancer medication patient
May 22, 2013 | bio-medicine.org
May 22, 2012 (Hackensack, NJ) John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the...
Read more...
therapy cell T-cells Cancer Theurer Anti-EBV Hematologi Hackensack immunology CAR Center Pathology&Immunology oncology M.D. manipulation MBChB Goy
May 22, 2013 | redliontrader.com
Post navigation ← felixsalmon: A timely reminder that it’s not just Apple: they all do it. http://t.co/3JQYNIMiAu There’s A Huge Flaw In Yahoo’s Monetization Plan For Tumblr (YHOO) → PALO ALTO, Calif., May 22, 2013 /PRNewswire/...
Read more...
Twitterfeed Enzoani CBMG TC-DC GEDC patient cell t.co Behrmann therapy Biomedicine Yenter
May 22, 2013 | finance.yahoo.com
NEW YORK, May 22, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit organization committed to developing immune system-based cancer treatments, is holding a series of ...
Read more...
All similar articles: 93 »
immunotherapy cancer Presented June CRI research treatment fightwithwhite webinars www.cancerresearch.org Institute
May 22, 2013 | yahoo.com
May 22 2013, 08:34 by: The Swiss Trader | about: MRK In April the global health care giant Merck & Co. , received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for its investigational...
Read more...
All similar articles: 433 »
Swiss Trader Merck lambrolizumab drug PD-1 therapy immunotherapy designation immune breakthrough melanoma cancer novel Tredaptive
May 22, 2013 | finance.yahoo.com
Celgene Corporation (CELG) 2013 UBS Global Healthcare Conference Call May 22, 2013, 11:30 am ET Executives Perry Karsen - EVP & COO Analysts Matt Roden - UBS Presentation Matt Roden - UBS Hi good morning ...
Read more...
apremilast POMALYST Celgene ABRAXANE REVLIMID psoriatic psoriasis pancreatic patient 2017 UBS franchise hematology oncology growth data arthritis cancer
May 22, 2013 | finance.yahoo.com
Immunovaccine Reports Financial Results for First Quarter of 2013 On May 16, 2013, Immunovaccine Inc. (TSXV: IMV .V) announced its financial and operational results for the quarter ended March 31, 2013. There was no revenue for...
Read more...
DPX-Survivac Immunovaccine Phase IMV patient vaccine immune clinical vaccination trial cancer study RSV
May 22, 2013 | estatevaults.com
Should you be taking vitamin B to protect against Alzheimer's? Vitamins B6 , B12 and folic acid Research published yesterday in the top journal Proceedings of the National Academy of Sciences, which showed that people in the...
Read more...
All similar articles: 49 »
shrinkage brain bunion CPR cancer apigenin B drug protect Alzheimer vitamin camomile health cell
May 22, 2013 | bullfax.com
By The Swiss Trader : In April the global health care giant Merck & Co. ( MRK ) , received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for its investigational antibody therapy ,...
Read more...
PD-1 designation therapy breakthrough immune drug cell receive Lambrolizumab camouflage checkpoint tumor tumor-specific protein Programmed immunomodulatory
May 22, 2013 | fool.com
As new immunotherapy drugs hope to turn metastatic cancer into a chronic manageable condition, or at least significantly prolong life in the near term, investors are understandably excited about their potential. And one company...
Read more...
David Williamson Wall Street MotleyDavid Obamacare Bristol upgrade immunotherapy $33 Bristol-Myers Squibb metastatic Need to takeaways $55 Motley far-reaching titan understandably Williamson Fool manageable health-care prolong investor Citi Know David health forefront
May 22, 2013 | barrons.com
By Sam Mamudi Bristol-Myers Squibb stock is up more than 7% today, and leading the Standard & Poor’s 500 index, thanks in part to a Citi Research note which upgraded the company to Buy and raised the stock’s price target to $55...
Read more...
Sam Mamudi Bristol-Myers Citi BMY immunotherapy stock CAGR BMS 2026 7 Baum $55 FY14e Smarten
May 22, 2013 | healthcanal.com
The body's own immune system’s fight against breast cancer is controlled by genetic ‘fine tuners’, known as microRNAs, according to a study published in Nature today1. Looking at 1,300 breast cancer samples, Cancer Research UK...
Read more...
cancer tuner genetic breast microRNAs subtype control fine body immune Research UK
May 22, 2013 | pr-inside.com
Advaxis, Inc., (Advaxis) is a biotechnology company. It develops next generation immunotherapies for cancer and infectious diseases. The company is developing products for the treatment of cervical, breast, prostate, ovarian,...
Read more...
All similar articles: 1067 »
Advaxis deal ADXS Pharmaceuticals&Healthcare GlobalData profile key Mergers Acquisitions research cancer Equity
May 22, 2013 | prlog.org
New research now shows that established drugs that alter the way the immune system behaves, may be effective in stopping vitiligo, a chronic autoimmune disease skin disease which affects nearly 100 million people worldwide.
Read more...
Vitiligo Research Foundation Vitiligo Neovir drug progression disease researcher worldwide immune re-purposing patient
May 21, 2013 | medicalnewstoday.com
Confirmed: Primary endpoint of significantly improving overall survival not met Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomized Phase III START* trial of its...
Read more...
L-BLP25 patient Non-Small CRT placebo cancer NSCLC lung III START endpoint